GERMANY - Apax, EQT and Warburg in race for EUR 2bn ratiopharm

The structured sales process began on 17 September, with comprehensive documents sent out at the beginning of October. VEM anticipates the completion of the transaction in the first quarter of 2010 at the earliest.

The ratiopharm group is a generics drugs manufacturer with a total turnover of EUR 1.7bn in 2008. ratiopharm consists partly of independently operating enterprises such as the smaller-scale generic producer CT Arzneimittel, or the Canadian Technilab group that was acquired in 2000. The vendor plans to sell the group as one, but may also consider selling the assets separately.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• DACH